These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 20580484)
1. Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Buonerba C; Palmieri G; Di Lorenzo G Eur Urol; 2010 Oct; 58(4):636-7. PubMed ID: 20580484 [No Abstract] [Full Text] [Related]
2. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. Sonpavde G; Sternberg CN Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874 [TBL] [Abstract][Full Text] [Related]
3. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Heidenreich A; Pfister D Eur Urol; 2012 Dec; 62(6):1201-4. PubMed ID: 22964168 [No Abstract] [Full Text] [Related]
4. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219 [TBL] [Abstract][Full Text] [Related]
5. Management of metastatic castration-resistant prostate cancer after first-line docetaxel. Harrington JA; Jones RJ Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426 [TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Armstrong AJ; George DJ Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. Di Lorenzo G; Buonerba C; Faiella A; Rescigno P; Rizzo M; Autorino R; Perdonà S; Riccardi N; Scagliorini S; Scognamiglio F; Masala D; Ferro M; Palmieri G; Aieta M; Marinelli A; Altieri V; De Placido S; Cartenì G BJU Int; 2011 Jan; 107(2):234-9. PubMed ID: 20590545 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Ito M; Saito K; Yasuda Y; Sukegawa G; Kubo Y; Numao N; Kitsukawa S; Urakami S; Yuasa T; Yamamoto S; Yonese J; Fukui I Urology; 2011 Nov; 78(5):1131-5. PubMed ID: 22054387 [TBL] [Abstract][Full Text] [Related]
19. Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus. Dorff TB; Quinn DI Ann Oncol; 2013 Feb; 24(2):270-272. PubMed ID: 23341479 [No Abstract] [Full Text] [Related]
20. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]